# A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects

> **NCT04488705** · PHASE1 · COMPLETED · sponsor: **Enterprise Therapeutics Ltd** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ETD002 - single dose
- **DRUG:** Placebo - single dose
- **DRUG:** ETD002 - 7 day repeat dose
- **DRUG:** Placebo - 7 day repeat dose
- **DRUG:** ETD002 - 14 day repeat dose
- **DRUG:** Placebo - 14 day repeat dose
- **DRUG:** Salbutamol

## Key facts

- **NCT ID:** NCT04488705
- **Lead sponsor:** Enterprise Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-13
- **Primary completion:** 2021-05-19
- **Final completion:** 2021-05-19
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04488705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04488705, "A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04488705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*